Wednesday, 25 Apr 2018

PsA/SpA

Datesort ascending Type Title Save
17 Dec 2017 Social FDA approves Xeljanz (tofacitinib) for use in adults with psoriatic arthritis, alone or in combo w/ MTX/DMARDs. But warns agains combining with biologics, cyclosporine or azathioprine as these have not been studied. https://t.co/ffsAfiaU70
16 Dec 2017 Social RT @DrPetryna: Delay in PSA Dx by >6 mo significantly increases risk of functional disability and structural damage #NYU 3rd annual seminar…
16 Dec 2017 Social RT @DrPetryna: Can effective treatment of psoriasis prevent onset of PSA? Prevention trial on the drawing board #psoriaticarthritis #preven…
15 Dec 2017 News FDA Approves Xeljanz for Use in Psoriatic Arthritis
11 Dec 2017 News 2017 Update of Treat to Target Recommendations for SpA/PsA
04 Dec 2017 News Ixekizumab (Taltz) FDA Approved for Psoriatic Arthritis
20 Nov 2017 News ACR17 Good News – Ankylosing Spondylitis and Spondyloarthritis
16 Nov 2017 Social IL-17–producing αβ T cell clones with psoriasis-specific antigen receptors exist in clinically resolved psoriatic s… https://t.co/Lj4B4dQ25N
16 Nov 2017 Social Check out Phil Mease's ACR17 video on Risankizumab (an IL-23 inhibitor) in Psoriatic arthritis - this was a late b… https://t.co/Vm0MbTowCt
14 Nov 2017 Social Smoking Paradox in PsA - a UK study shows smoking was positively related to PsA risk in the general population, but… https://t.co/N7ZEgUYHhH
13 Nov 2017 News MTX Doubles Hepatotoxicity Risk in Psoriasis Patients
10 Nov 2017 Social RT @msmassarotti: Predictors of radiographic progression in patients with nr-axSpA: conclusions from DESIR trial - R. Landewé SPARTAN-ASAS-…
10 Nov 2017 Social RT @synovialjoints: Bone marrow oedema in sacroiliac joints is common (30-40%) in young athletes and is most frequent in the posterior lowe…
10 Nov 2017 Social RT @doctorakerkar: Only 9-14% people with chronic backache see a rheumatologist #ACR17 https://t.co/jq5Y0xFjE6
10 Nov 2017 News Several Agents Score on Radiographic Progression in Psoriatic Arthritis
09 Nov 2017 Social RT @msmassarotti: CVD risk in axSpA - Nigil Haroon SPARTAN-GRAPPA-ASAS Symposium #ACR17 https://t.co/BtpXBszcUb
09 Nov 2017 Social RT @japaoli19: @RheumNow Agree. Only 6% were strong recommendations. Glad they addressed comorbidities but management not necessarily consi…
09 Nov 2017 Social RT @rheumnews1: New PsA guideline expected in 2018. #ACR17 https://t.co/c7Y8GiBv4q https://t.co/g7wtIBXXko
09 Nov 2017 Social @japaoli19 These are mostly of little or low evidence, are confusing and not prescriptive and without clear financ… https://t.co/7DG9AjQ9UH
09 Nov 2017 Social RT @DrPetryna: Smoking paradox: smoking assoc w/⬆️risk of PsA in gen population HR1.27 but w/ ⬇️risk of PsA in PSO (HR 0.91) population-bas…